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Complete Resection of Pulmonary Metastatic Melanoma
Jae  Jun  Kim,  M.D.*,  Jae-Kil  Park,  M.D.*,  Young-Pil  Wang,  M.D.*
Background:  The prognosis of melanoma metastasized to other organs is very poor. There have been many stud-
ies on metastatic melanoma in Western society, but there have been few studies done in Korea because of the 
small number of cases. Materials and Methods: A retrospective review of 7 patients who underwent complete re-
section of pulmonary metastases from melanoma from January 2005 to December 2009 was performed. When the 
primary lesion was controlled or simultaneously controllable and no other metastatic lesion was found, pulmonary 
resections were performed. We analyzed the clinical prognoses after the initial melanoma diagnosis. Results: Of 
the seven patients, one was male and six were female. The mean age was 58.2 years (range 45∼71). Six pa-
tients had a single pulmonary lesion and one patient had three lesions confined to the same lobe. The mean dis-
ease-free interval was 43.5 months (0∼146 months). Before pulmonary resection, 4 patients had received systemic 
therapy. After pulmonary resection, 6 patients received systemic therapy. Complete resection was confirmed histo-
logically. The metastasectomy was performed by wedge resection (6 patients) or lobectomy (1 patient). There were 
no mortalities or complications. After pulmonary resection, 1 patient had recurrent multiple lesions in the lung and 
4 patients had metastases to other organs. The organs were the liver, brain, pleura, and lymph nodes. The mean 
observation time was 31.6 months and 3 patients died during observation. The mean survival was 27.7 months 
(14∼60 months) and the 1-year and 3-year survival rates were 100% and 42%, respectively. Conclusion: When 
patients were selected carefully, the complete resection of pulmonary metastatic lesions was considered a major 
therapeutic tool.
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INTRODUCTION
The  prevalence  of  melanoma  is  rapidly  increasing  because 
of  the  spread  of  the  Westernized  lifestyle  and  diet.  It  has 
been  reported  that  55,100  people  in  the  United  States  were 
diagnosed  with  melanoma  in  2004,  and  that  melanoma  con-
stituted 0.2% of all cancer cases in Korea, according to 2007 
Korean  Ministry  of  Health  and  Welfare  statistics  [1,2].  After 
the treatment of melanoma at the primary site, melanoma can 
recur  locally  and  can  metastasize  to  any  organ.  30%  of  all 
melanoma  patients  will  have  metastases  [3].  Metastatic  mela-
noma  is  usually  associated  with  a  dismal  prognosis.  The 
mean survival is only 6 to 8 months, and the 5-year survival 
rate  is  about  5%  [4-6].  In  general,  the  prognosis  depends  on 
the  initial  site  of  metastasis.  More  than  80%  of  patients  with 
metastatic  melanoma  initially  show  only  one  distant  organ 
site involved. The most common metastatic organ is the lung, 
and about 40% of patients with metastatic melanoma initially Jae Jun Kim, et al
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Table 1. Patient characteristics for primary melanoma
Patient Age/Gender Primary  site
Postoperative  systemic 
therapy
1 63/F Chest  wall Yes
2 58/F Right  heel Yes
3 45/F Right  maxilla No
4 71/F Right  middle  meatus No
5 59/F Right  heal Yes
6 59/M Right  hand  thumb No
7 53/F Vulva Yes
Table 2. Patient characteristics for pulmonary metastasis
Patients
DFI 
(months)
Location
Tumor  number 
and  size  (largest)
Performance 
status  (ECOG)
1 54 RUL One/0.7  cm 1
2 29 RLL One/0.6  cm 1
3 30 LLL One/1.2  cm 0
40 L L L O n e / 1   c m 2
5 24 RLL One/1.2  cm 0
6 22 LLL Three/2.9  cm 1
71 4 6L L L O n e / 2 . 5   c m 0
DFI=Disease  free  interval;  ECOG=European  Cooperative  Oncol-
ogy  Group;  RUL=Right  upper  lobe;  RLL=Right  lower  lobe; 
LLL=Left  lower  lobe.  show  isolated  pulmonary  metastasis.  Progress  of  the  disease 
can be attenuated by complete pulmonary metastatectomy [5]. 
    Complete  response  to  systemic  therapy  is  very  rare  (10∼
15%),  making  complete  resection  a  very  effective  treatment 
modality  in  pulmonary  metastatic  melanoma  [5,7].  Complete 
resection  has  been  shown  in  many  studies  to  be  associated 
with  a  5-year  survival  rate  as  high  as  39%,  compared  to  a 
3%  to  5%  5-year  survival  rate  for  systemic  therapy  patients 
[3,4,8].
    We  retrospectively  analyzed  the  clinical  outcome  of  com-
plete resection performed in patients with pulmonary metasta-
static  melanoma.
MATERIALS AND METHODS
    A retrospective clinical review was performed of the medi-
cal records of 7 patients who underwent complete surgical re-
section  of  pulmonary  metastases  from  melanoma  between 
January  2005  and  December  2009  after  the  primary  melano-
ma  had  been  controlled.  The  indications  for  metastasectomy 
included  a  curable  or  cured  primary  tumor,  no  evidence  of 
extra-pulmonary  metastases,  complete  resectability  of  the  pul-
monary  metastasis,  and  the  patient  being  in  a  condition  to 
tolerate  surgery.  We  obtained  information  regarding  the  dis-
ease-free interval (DFI) and other organ metastasis after meta-
stasectomy from medical records. Pulmonary metastatic mela-
noma  was  diagnosed  when  the  HMB  45  and  the  S-100  im-
munohistochemistry  stain  of  the  specimen  were  positive.  One 
of the 7 patients with coincidental lesions at the lung and the 
primary  site  underwent  pulmonary  metastasectomy  and  pri-
mary  melanoma  resection  simultaneously.  The  DFI  was  de-
fined  as  the  time  between  the  ocurrence  of  pulmonary  meta-
stasis  and  resection  of  the  primary  melanoma.  The  survival 
curves  were  calculated  by  the  Kaplan-Meier  method  and  dif-
ferences  were  tested  by  the  log-rank  test.
RESULTS
    There was one male and six female patients. The mean age 
was 58.2 years (range 45∼71). Six patients had a single pul-
monary  lesion  and  one  patient  had  three  lesions  confined  to 
the same lobe. The pulmonary metastasectomy was performed 
by  wedge  resection  (6  patients)  or  lobectomy  (1  patient). 
Complete  resection  was  performed  in  all  patients  and  con-
firmed  histologically.  There  were  no  mortalities  or  complica-
tions  after  operation.  The  mean  DFI  was  43.5  months  (0∼
146  months).  Before  pulmonary  resection,  4  patients  had  re-
ceived systemic therapy. After pulmonary resection, 6 patients 
received  systemic  therapy.  After  pulmonary  resection,  1  pa-
tient had recurrent multiple lesions in the lung and 4 patients 
had  metastases  to  other  organs.  The  organs  were  the  liver, 
b r a i n ,  p l e u r a ,  a n d  l y m p h  n o d e s .  The  mean  observation  time 
was 31.6 months and 3 patients died during observation. The 
mean  survival  was  27.7  months  (14∼6 0  m o n t h s )  a n d  t h e  
1-year  and  3-year  survival  rates  were  100%  and  42%,  re-
spectively  (Table  1∼3,  Fig.  1).Pulmonary Metastatic Melanoma
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Table 3. Characteristics of pulmonary metastasectomy
Patients
Surgical 
procedure
Survival  time
(month)
Post-operative 
systemic  therapy
Survival
1 Wedge  resection 60 Yes Alive
2 Wedge  resection 24 Yes Dead
3 Wedge  resection 14 Yes Alive
4 Wedge  resection 36 No Alive
5 Wedge  resection 29 Yes Dead
6L o b e c t o m y 1 5 Y e s D e a d
7 Wedge  resection 16 Yes Alive
Fig. 1. Overall survival of patients. The mean survival was 27.7 
months and The 1-year and 3-year survival rates were 100% and 
42%, respectively.
DISCUSSION
    Melanoma  is  a  malignant  tumor  of  melanocytes  from  the 
neural  crest.  Melanocytes  are  found  predominantly  in  the 
skin, but are also found in all part of body [9,10]. The preva-
lence of melanoma is rapidly increasing because of the spread 
of  the  Westernized  lifestyle  and  diet  in  the  Republic  of 
Korea.  Melanoma  constituted  0.2%  of  all  cancer  cases  in 
Korea  according  to  a  2007  report  by  the  Korean  Ministry  of 
Health  and  Welfare  [6,10].  After  the  primary  melanoma  is 
controlled,  recurrence  may  develop.  About  30%  of  patients 
have  metastasis.  More  than  80%  of  patients  with  metastatic 
melanoma initially show only one distant organ site involved. 
The  lung  is  the  most  common  organ  involved,  with  about 
40%  of  patients  showing  isolated  pulmonary  metastasis  [3,5, 
11-13]. Metastatic melanoma is usually associated with a dis-
m a l  p r o g n o s i s .  T h e  m e a n  s u r v i v a l  o f  p a t i e n t s  w i t h  m e t a s t a t i c  
melanoma  is  6  to  8  months  [4,5,8,11,14].  There  are  many 
studies  for  metastatic  melanoma  in  Western  society  but  there 
are  few  studies  in  Korea  because  of  the  small  number  of 
cases.  Many  studies  have  shown  that  systemic  chemotherapy 
and  immune  therapy  have  little  effect  on  metastatic  melano-
ma,  especially  on  lesions  over  2  cm  in  size  [4,5,8,11,12,14, 
15].  Unlike  systemic  therapy,  surgery  can  provide  a  patient 
with  immediate  disease-free  status  from  metastatic  melanoma 
with little morbidity and improved long-term survival [15,16]. 
Only  complete  resection  can  improve  the  long-term  survival 
of the patient, especially those with a single metastatic lesion 
[14].  Among  all  distant  metastases  from  malignant  melano-
mas of the skin, pulmonary metastasis occurs most frequently. 
Patients  are  usually  asymptomatic,  so  PET-CT  and  chest  CT 
are  needed  in  follow-up  after  the  primary  site  is  controlled. 
Studies  combining  PET-CT  and  conventional  chest  CT  show 
88%  sensitivity,  91%  specificity,  15%  false  negative,  and 
10%  false positive. This process can be  used to  define meta-
static lesions with a size of 5 mm  [3,5,6,8,14,17,18]. A pre-
vious study (IRLM, International Registry of Lung Metastasis) 
has  suggested  some  significant  prognostic  factors  for  meta-
static  melanoma.  Factors  included  the  number  of  pulmonary 
nodules,  the  DFI,  the  site  of  metastasis  (visceral  vs.  non-vis-
ceral),  and  the  completeness  of  resection.  The  completeness 
of  resection  is  the  most  important  of  these  factors  [3,5,7,15, 
16].  One  study  showed  that  the  patients  with  complete  re-
section had a 5-year survival of 29% and a mean survival of 
40  months  [18].  Another  study  showed  that  the  patients  with 
incomplete  resection  had  a  5-year  survival  of  13%  and  a 
mean  survival  rate  of  11  months  [12].  The  5-year  survival 
rate  of  patients  with  a  DFI  over  36  months  was  30%,  com-
pared  to  17%  in  the  patients  with  a  DFI  below  36  months. 
The  DFI  in  our  study  was  45.5  months,  but  the  5-year  sur-
vival  could  not  be  calculated  using  the  DFI  because  of  the 
small  number  of  cases.  Although  the  prognosis  of  metastatic 
melanoma  is  poor,  complete  resection  can  improve  long-term 
survival.  Even  incomplete  resection  can  provide  longer  sur-
vival  than  systemic  therapy,  which  means  resection  itself  can 
attenuate the tumor burden and improve immunity [3,5,11,12]. 
By mechanical reduction of the immunosuppressive factors of 
the  tumor,  surgery  can  restore i m m u n i t y  t o  a  l e v e l  t h a t  c o n -Jae Jun Kim, et al
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trols the progression of metastases and ensures a durable clin-
ical  response.  The  current  AJCC  staging  system  categorizes 
the M stage by metastatic site because of different prognosis. 
Skin, subcutaneous tissues, and distant lymph node metastases 
are  categorized  as  M1a.  Pulmonary  metastases  are  identified 
as  M1b.  Metastases  to  other  visceral  sites,  or  patients  with 
skin,  soft tissue,  or lung  metastases have M1c disease  [7,11]. 
Patients with pulmonary melanoma metastases tend to survive 
longer  than  patients  with  other  visceral  metastases,  so  they 
may  need aggressive treatment [3,10,14]. Surgical therapy for 
pulmonary metastasis is not a new treatment modality, as the 
first  metastasectomy  was  performed  more  than  50  years  ago   
[15].  In  Korea,  the  surgery  is  usually  limited  to  the  occa-
sional  complete  resection  of  a  solitary  visceral  metastasis,  or 
for  palliative  resection  for  symptomatic  metastases  causing 
bowel  obstruction  and  brain  hemorrhage,  because  of  little  in-
s i g h t  a n d  a t t e n t i o n  [ 1 0 , 1 1 , 1 8 ] .  T h e  K o r e a n  c l i n i c a l  p r o t o c o l  
for defining the pathology of a malignant melanoma is differ-
e n t  f r o m  t h a t  o f  W e s t e r n  c l i n i cians.  The  1-year  and  5-year 
survival rates in our study were 100% and 42%, respectively. 
Although  our  study  involved  few  cases,  we  observed  the  ef-
fectiveness  of  complete  resection  in  metastatic  melanoma. 
M e l a n o m a  i s  n o t  y e t  a  c o m m o nly  encountered  cancer  in 
Korea.  Because  there  were  only  7  cases  in  our  study,  further 
studies  will  be  needed. 
CONCLUSION
The  prognosis  of  melanoma  metastasis  to  other  organs  is 
very  poor.  But  when  the  patients  were  selected  carefully,  the 
complete  resection  of  pulmonary  metastatic  lesions  can  im-
prove  survival  of  the  patients  with  pulmonary  metastatic 
melanoma.
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